179 related articles for article (PubMed ID: 9499111)
1. Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity.
LaCasse RA; Follis KE; Moudgil T; Trahey M; Binley JM; Planelles V; Zolla-Pazner S; Nunberg JH
J Virol; 1998 Mar; 72(3):2491-5. PubMed ID: 9499111
[TBL] [Abstract][Full Text] [Related]
2. Continued utilization of CCR5 coreceptor by a newly derived T-cell line-adapted isolate of human immunodeficiency virus type 1.
Follis KE; Trahey M; LaCasse RA; Nunberg JH
J Virol; 1998 Sep; 72(9):7603-8. PubMed ID: 9696861
[TBL] [Abstract][Full Text] [Related]
3. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
4. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
Martín J; LaBranche CC; González-Scarano F
J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
[TBL] [Abstract][Full Text] [Related]
5. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
[TBL] [Abstract][Full Text] [Related]
6. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.
Spenlehauer C; Saragosti S; Fleury HJ; Kirn A; Aubertin AM; Moog C
J Virol; 1998 Dec; 72(12):9855-64. PubMed ID: 9811721
[TBL] [Abstract][Full Text] [Related]
7. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies.
Beddows S; Louisirirotchanakul S; Cheingsong-Popov R; Easterbrook PJ; Simmonds P; Weber J
J Gen Virol; 1998 Jan; 79 ( Pt 1)():77-82. PubMed ID: 9460926
[TBL] [Abstract][Full Text] [Related]
8. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
[TBL] [Abstract][Full Text] [Related]
9. Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylation.
Shi Y; Brandin E; Vincic E; Jansson M; Blaxhult A; Gyllensten K; Moberg L; Broström C; Fenyö EM; Albert J
J Gen Virol; 2005 Dec; 86(Pt 12):3385-3396. PubMed ID: 16298986
[TBL] [Abstract][Full Text] [Related]
10. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
[TBL] [Abstract][Full Text] [Related]
11. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
Verrier F; Borman AM; Brand D; Girard M
AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469
[TBL] [Abstract][Full Text] [Related]
12. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.
Cecilia D; KewalRamani VN; O'Leary J; Volsky B; Nyambi P; Burda S; Xu S; Littman DR; Zolla-Pazner S
J Virol; 1998 Sep; 72(9):6988-96. PubMed ID: 9696790
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.
Derdeyn CA; Decker JM; Sfakianos JN; Zhang Z; O'Brien WA; Ratner L; Shaw GM; Hunter E
J Virol; 2001 Sep; 75(18):8605-14. PubMed ID: 11507206
[TBL] [Abstract][Full Text] [Related]
14. Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism.
Kato K; Sato H; Takebe Y
J Virol; 1999 Jul; 73(7):5520-6. PubMed ID: 10364300
[TBL] [Abstract][Full Text] [Related]
15. Engineered CD4- and CXCR4-using simian immunodeficiency virus from African green monkeys is neutralization sensitive and replicates in nonstimulated lymphocytes.
König RR; Flory E; Steidl S; Neumann J; Coulibaly C; Holznagel E; Holzammer S; Norley S; Cichutek K
J Virol; 2002 Nov; 76(21):10627-36. PubMed ID: 12368305
[TBL] [Abstract][Full Text] [Related]
16. Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1.
York J; Follis KE; Trahey M; Nyambi PN; Zolla-Pazner S; Nunberg JH
J Virol; 2001 Mar; 75(6):2741-52. PubMed ID: 11222697
[TBL] [Abstract][Full Text] [Related]
17. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary-isolate quasispecies.
Singh A; Collman RG
J Virol; 2000 Nov; 74(21):10229-35. PubMed ID: 11024154
[TBL] [Abstract][Full Text] [Related]
19. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.
Park EJ; Vujcic LK; Anand R; Theodore TS; Quinnan GV
J Virol; 1998 Sep; 72(9):7099-107. PubMed ID: 9696803
[TBL] [Abstract][Full Text] [Related]
20. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor.
Trkola A; Matthews J; Gordon C; Ketas T; Moore JP
J Virol; 1999 Nov; 73(11):8966-74. PubMed ID: 10516002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
